-
Mashup Score: 0Frontline Nivolumab/Ipilimumab Improves OS in Advanced NSCLC, Irrespective of Mutational Status - 2 year(s) ago
The dual immunotherapy combination comprised of nivolumab and ipilimumab improved overall survival vs chemotherapy in patients with advanced non–small cell lung cancer, irrespective of KRAS, TP53, or STK11 mutational status, according to data from exploratory analyses of part 1 of the CheckMate-227 trial.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Frontline Nivolumab/Ipilimumab Improves OS in Advanced NSCLC, Irrespective of Mutational Status - 2 year(s) ago
The dual immunotherapy combination comprised of nivolumab and ipilimumab improved overall survival vs chemotherapy in patients with advanced non–small cell lung cancer, irrespective of KRAS, TP53, or STK11 mutational status, according to data from exploratory analyses of part 1 of the CheckMate-227 trial.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 2ESMO Immuno-Oncology Congress | OncologyPRO - 2 year(s) ago
OncologyPRO is the home of ESMO’s educational & scientific resources, with exclusive content for ESMO members such as ESMO’s Congresses webcasts,
Source: oncologypro.esmo.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 2Frontline Nivolumab/Ipilimumab Improves OS in Advanced NSCLC, Irrespective of Mutational Status - 2 year(s) ago
The dual immunotherapy combination comprised of nivolumab and ipilimumab improved overall survival vs chemotherapy in patients with advanced non–small cell lung cancer, irrespective of KRAS, TP53, or STK11 mutational status, according to data from exploratory analyses of part 1 of the CheckMate-227 trial.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Head and neck cancer, immunotherapy combination is promising - 2 year(s) ago
Results from the RATIONALE 309 study show benefit in patients with nasopharyngeal cancer
Source: Daily ReporterCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
#ESMOImmuno21: A new immunotherapy-based combination is promising in #nasopharyngealcancer. Tislelizumab in combination w/ gemcitabine & cisplatin prolonged PFS compared w/ chemotherapy alone in the RATIONALE 309 study. https://t.co/dYS78BYG6L #hncsm #immunotherapy @licitra_lisa https://t.co/bjs9iagdKQ
-
-
Mashup Score: 3Biomarkers for immunotherapy: where are we? - 2 year(s) ago
For Andrew Furness, Royal Marsden NHS Foundation Trust, London, no single biomarker is likely to reflect the complexity of the tumour microenvironment
Source: Daily ReporterCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
#ESMOImmuno21: The future is in the hands of tools built on combinations of #biomarkers as no single one likely to reflect complexity of tumour microenvironment or account for tumour evolution Educational Session 10/12 at 14:30 https://t.co/xFqPdSfEb1 @ajsfurness #immunotherapy https://t.co/PLvky2970c
-
-
Mashup Score: 11How much is enough with immunotherapy? - 2 year(s) ago
For Dr Jedd Wolchok, one of the biggest challenges in the field is knowing how and when to de-escalate immunotherapy
Source: Daily ReporterCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
#ESMOImmuno21: Award 2020 lecture 'Checkpoint blockade therapy for #melanoma: Combinations to improve outcomes', Jedd D. Wolchok, ESMO #Immuno-Oncology 2020 Award winner 🗓️ 10/12, 12:35 CET Daily Reporter article 'How much is enough with #immunotherapy?': https://t.co/0fG7rsfRBI https://t.co/4cwvbyZ5n1
-
-
Mashup Score: 9Refining patient selection for atezolizumab in resected NSCLC - 2 year(s) ago
An exploratory analysis of the IMpower010 trial confirms that there is a correlation between tumour-cell PD-L1 expression and disease-free survival
Source: Daily ReporterCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
#ESMOImmuno21: Refining pts selection for atezolizumab in resected #NSCLC. Results from an exploratory analysis of the IMpower010 trial confirm a correlation between tumour-cell PD-L1 expression & disease-free survival https://t.co/1qWz7sOuCp @MartinReck2 #immunotherapy #lcsm https://t.co/WXveAGSYMl
-
-
Mashup Score: 6NSCLC, ctDNA changes after neoadjuvant therapy - 2 year(s) ago
A study associates reductions in ctDNA with major pathologic response following neoadjuvant atezolizumab in resectable stage IB–IIIB NSCLC
Source: Daily ReporterCategories: Hem/Oncs, Latest HeadlinesTweet-
RT @myESMO: #ESMOImmuno21: Can #ctDNA changes after neoadjuvant therapy inform management of early #NSCLC? 👉 https://t.co/OJZvNLoKI9 #immu…
-
-
Mashup Score: 0Defining patient groups for immunotherapy - 2 year(s) ago
Sub-group analyses of CheckMate 227 part 1 provide reassurance but no definite guidance regarding standard treatment for different patient sub-groups
Source: Daily ReporterCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
Nivolumab + ipilimumab improved OS vs chemo with advanced non–small cell lung cancer, irrespective of KRAS, TP53, or STK11 mutational status, according to data from exploratory analyses of part 1 of the CheckMate-227 trial. @myESMO #ESMOImmuno21 #lcsm https://t.co/GLIe0IxDpv